ArticleEvidence-based complementary and alternative medicine : eCAM2015
Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice.
Article in Evidence-based complementary and alternative medicine : eCAM, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Berberine's impact on health: Comprehensive biological, pharmacological, and nutritional perspectives.Metabolism open · 2025Review
- Berberine ameliorates acute hyperglycemia and hypoinsulinemia induced by ketamine/xylazine in rats: role of alphaBMC veterinary research · 2025Article
- Fabrication and evaluation of BerNPs regarding the growth and development ofBeilstein journal of nanotechnology · 2025Article
- Protective effects of berberine-loaded chitosan/solid lipid nanoparticles in streptozotocin-induced gestational diabetes mellitus rats.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects.International journal of nanomedicine · 2025Review
- Harnessing the Power of Traditional Chinese Medicine in Cancer Treatment: The Role of Nanocarriers.International journal of nanomedicine · 2025Review
- Research progress on pharmacological effects and bioavailability of berberine.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Review
- Herbal Medicine Nanocrystals: A Potential Novel Therapeutic Strategy.Molecules (Basel, Switzerland) · 2023Review
- A sustained-release phospholipid-based phase separation gel loaded with berberine for treating rheumatoid arthritis.Frontiers in pharmacology · 2023Article
- The Interaction of Food Allergy and Diabetes: Food Allergy Effects on Diabetic Mice by Intestinal Barrier Destruction and Glucagon-like Peptide 1 Reduction in Jejunum.Foods (Basel, Switzerland) · 2022Article
- Cytokine storm-calming property of the isoquinoline alkaloids inFrontiers in pharmacology · 2022Review
- Role of Nanotechnology and Their Perspectives in the Treatment of Kidney Diseases.Frontiers in genetics · 2021Review
- Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches.Biomedicines · 2020Review
- Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy.International journal of molecular sciences · 2020Review
- Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds.International journal of nanomedicine · 2020Review
- Nanoparticle Delivery Systems in the Treatment of Diabetes Complications.Molecules (Basel, Switzerland) · 2019Review
- Preparation and Characterization of Erythrocyte Membrane-Camouflaged Berberine Hydrochloride-Loaded Gelatin Nanoparticles.Pharmaceutics · 2019Article
- Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine.Journal of nanobiotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine (Ber), an isoquinoline derivative alkaloid and active ingredient of Coptis, has been demonstrated to possess antidiabetic activities. However its low oral bioavailability restricts its clinical application. In this report, Ber nanosuspension (Ber-NS) composed of Ber and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) was prepared by high pressure homogenization technique. Antidiabetic effects of Ber-NS relative to efficacy of bulk Ber were evaluated in streptozotocin (STZ) induced diabetic C57BL/6 mice. The particle size and zeta potential of Ber-NS were 73.1 ± 3.7 nm and 6.99 ± 0.17 mV, respectively. Ber-NS (50 mg/kg) treatment via oral gavage for 8 weeks resulted in a superior hypoglycemic and total cholesterol (TC) and body weight reduction effects compared to an equivalent dose of bulk Ber and metformin (Met, 300 mg/kg). These data indicate that a low dosage Ber-NS decreases blood glucose and improves lipid metabolism in type 2 diabetic C57BL/6 mice. These results suggest that the delivery of Ber as a nanosuspension is a promising approach for treating type 2 diabetes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.